Group 1 - Vertex Pharmaceuticals has successfully launched its fifth CFTR modulator, ALYFTREK, in the U.S. [3] - The company is building momentum for the CASGEVY launch, which is considered a foundational year after 2024 [3] - Vertex has also recently launched JOURNAVX for acute pain management, marking its entry into a new therapeutic area [2][3] Group 2 - The company is focused on executing its launches and expanding its pipeline over the next 12 to 18 months [2] - Vertex is strategically positioned with multiple product launches, enhancing its market presence in both cystic fibrosis and pain management [2][3]

Tarsus Pharmaceuticals (TARS) FY 2025 Conference May 20, 2025 03:00 PM ET Speaker0 All right. So I guess we'll get started here. Welcome, everyone. My name is Matthew Caulfield. I'm a senior biotech analyst here at H. C. Wainwright. Our next speaker or next guest will be Tarsus Pharmaceuticals, and we're joined by Jeff Farrow, CFO and Chief Strategy Officer. So Jeff, thank you so much for joining us. Thank you for having us. Welcome to Tarsus. So to start off, maybe we could discuss the approved product, Xt ...